BlackRock Inc. Has $135.57 Million Stake in Diplomat Pharmacy Inc (DPLO)
BlackRock Inc. grew its stake in Diplomat Pharmacy Inc (NYSE:DPLO) by 3.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,754,710 shares of the company’s stock after acquiring an additional 237,500 shares during the quarter. BlackRock Inc. owned about 9.81% of Diplomat Pharmacy worth $135,566,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in Diplomat Pharmacy during the 3rd quarter worth $191,000. Piedmont Investment Advisors LLC purchased a new position in Diplomat Pharmacy during the 3rd quarter worth $216,000. Fox Run Management L.L.C. purchased a new position in Diplomat Pharmacy during the 4th quarter worth $244,000. D.A. Davidson & CO. purchased a new position in Diplomat Pharmacy during the 4th quarter worth $278,000. Finally, Invictus RG grew its stake in Diplomat Pharmacy by 24.4% during the 3rd quarter. Invictus RG now owns 13,820 shares of the company’s stock worth $286,000 after buying an additional 2,707 shares during the last quarter. Institutional investors and hedge funds own 64.64% of the company’s stock.
DPLO has been the topic of several research analyst reports. Deutsche Bank initiated coverage on Diplomat Pharmacy in a research note on Monday, December 4th. They set a “buy” rating and a $22.00 target price on the stock. Leerink Swann upgraded Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 target price on the stock in a research note on Monday, December 11th. Needham & Company LLC boosted their target price on Diplomat Pharmacy from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, January 8th. Mizuho set a $25.00 price target on Diplomat Pharmacy and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, Credit Suisse Group raised Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 price target for the company in a research report on Thursday, January 25th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Diplomat Pharmacy currently has a consensus rating of “Hold” and a consensus target price of $25.38.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.18 EPS for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.02. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the firm posted $0.08 EPS. The firm’s revenue was up .9% compared to the same quarter last year. equities analysts forecast that Diplomat Pharmacy Inc will post 0.94 earnings per share for the current year.
In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 2,150,000 shares of Diplomat Pharmacy stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $20.65, for a total transaction of $44,397,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 30.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “BlackRock Inc. Has $135.57 Million Stake in Diplomat Pharmacy Inc (DPLO)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/blackrock-inc-has-135-57-million-stake-in-diplomat-pharmacy-inc-dplo/1959050.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.